GenEditBio to Present Preclinical Data on its Delivery Technology Platform and Drug Pipeline at the 28th Annual Meeting of the American Society of Gene and Cell Therapy

[April 29, 2025] – GenEditBio Limited (“GenEditBio”), a biotechnology start-up company focusing on genome-editing therapeutic solutions through the discovery of novel Cas nuclease and the development of safe and efficient cargo delivery platforms, today announced that the Company will have two oral and poster talk presentations of preclinical data on its delivery technology platform and drug pipeline at the 28^th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), New Orleans, Louisiana, USA, May 13-17, 2025.

“We are excited to showcase our pioneering preclinical work on the in vivo delivery of genome-editing agents using our flagship platform called protein delivery vehicle (PDV). Our data demonstrates that PDV exhibits a high safety profile, with virtually undetectable off-target effect while achieving superior editing efficiency. PDV is well-tolerated in local ocular injection in non-human primates and represents a clinically promising delivery tool for the treatment of hereditary eye diseases such as corneal dystrophy,” said Zongli ZHENG, PhD, Chairman and Co-Founder of GenEditBio.

“GenEditBio is actively seeking strategic collaborations worldwide to accelerate our genome-editing pipeline into clinical trials. Partnerships with academic institutions, medical schools, pharmaceutical leaders, and investors will be essential to translate our innovative delivery technology platform and foundational preclinical effort into disease-modifying clinical solutions to benefit patients,” said Tian ZHU, PhD, CEO and Co-Founder of GenEditBio.

Details of the Company’s upcoming presentations are as follows -

Oral Presentation

Title: Engineered Protein Delivery Vehicles Enable Single Intrastromal CRISPR-Cas9 Therapy for TGFBI Corneal Dystrophies with High Efficacy and Safety: A Comprehensive Preclinical Assessment in Non-Human Primates

Abstract #: 270
Session: Emerging Delivery Platforms for In Vivo Gene Editing
Presenter: Zihua JIANG, BSc (Team Lead, Novel Delivery)
Date and Time: May 16, 2025, 08:30 am – 08:45 pm CDT

Location: Room 278-282

Poster Talk Presentation

Title: Safe and Efficient Editing of Novel CRISPR-Cas Ribonucleoprotein Complexes Delivered by Engineered Protein Delivery Vehicle

Abstract #: 497
Session: Poster Talk
Presenter: Bang WANG, PhD (Principal Scientist, Research & Technology)
Date and Time: May 15, 2025, 12:15 pm – 13:00 pm CDT

Location: Exhibit Theater

About GenEditBio

Established in 2021 and headquartered in Hong Kong, China, GenEditBio is a gene therapy start-up company with an overarching strategic goal of providing potentially curative, once-and-done and programmable in vivo genome editing-based therapeutic solutions (dubbed “DNA surgery”) with high safety profile, unmatched precision, and affordable access for genetic diseases with unmet needs. The Company’s core areas of focus include novel Cas nuclease discovery and safe and efficient cargo delivery utilizing lipid nanoparticle (LNP) and engineered protein delivery vehicle (PDV). We have research laboratories and supporting offices in Hong Kong, Beijing, and Boston. GenEditBio is financially backed by top-tier life science investors, including Qiming Venture Partners, Fangyuan Capital, Center Biotherapeutics, Lumosa Therapeutics, HKSTP Venture Fund, and other investors.

Contact

bd@geneditbio.com